- Home Page
- What's New?
- Tumor Types
- Molecular Causes of Cancer
- Biological Pathways
- Therapeutic Targets
- Pipeline Molecules
- Research Education
- Clinical Trials
- Resources
- Contact Us
Related Resources for this page:
- Tumor Types
- Molecular Causes of Cancer
- Biological Pathways
- Therapeutic Targets
- Future Directions
- Antibody-Drug conjugates
- HER Signaling
- Receptor-Mediated Endocytosis
- Anti-HER3/EGFR MAb (MEHD7945A)
- Anti-PDL1 (MPDL3280A)
- Cytotoxic agent
- What are ADCs?
- Stable linker
- Monoclonal antibody
- Current research in ADCs
- Targeting cancers with ADCs
- Glossary
- A brief history of ADCs
- How are ADCs designed to work?
- Research ADCs
- Multimedia Resources
- HER2:HER3 dimer
- Glossary
- HER1/EGFR evaluation
- HER1/EGFR in lung cancer
- HER1/EGFR in pancreatic cancer
- HER1/EGFR and prognosis
- Summary
- HER1/EGFR as a therapeutic target
- HER2 in breast cancer
- HER2 detection methods
- HER2 dysregulation
- HER2
- HER2 in ovarian cancer
- HER2 and prognosis
- Summary
- HER2 as a therapeutic target
- HER3 in breast cancer
- HER3 dysregulation
- HER3 evaluation
- HER3
- HER3 in ovarian cancer
- Summary
- HER3 as a therapeutic target
- HER4
- HER pathways slide decks and videos
- Receptor activation
- Cancer effects
- Dimerization
- Overview
- HER ligands
- HER receptors
- Summary
- Therapeutic potential of HER pathways
- Research MET
- What is Met?
- Glycoengineered Antibodies
- Non-Antibody Biologics
- Targeted Small Molecules
- Apoptosis
- MAPK Signaling
- PI3K/Akt/mTOR Signaling
- Anti-HER3/EGFR MAb (MEHD7945A)
- MEK Inhibitor (GDC-0973)
- PI3K Inhibitor (GDC-0941)
- Glossary
- Resisting apoptosis
- HER2:HER3 dimer
- Glossary
- HER1/EGFR evaluation
- HER1/EGFR in lung cancer
- HER1/EGFR in pancreatic cancer
- HER1/EGFR and prognosis
- Summary
- HER1/EGFR as a therapeutic target
- HER2 in breast cancer
- HER2 detection methods
- HER2 dysregulation
- HER2
- HER2 in ovarian cancer
- HER2 and prognosis
- Summary
- HER2 as a therapeutic target
- HER3 in breast cancer
- HER3 dysregulation
- HER3 evaluation
- HER3
- HER3 in ovarian cancer
- Summary
- HER3 as a therapeutic target
- HER4
- HER pathways slide decks and videos
- Receptor activation
- Cancer effects
- Dimerization
- Overview
- HER ligands
- HER receptors
- Summary
- Therapeutic potential of HER pathways
- Research MET
- What is Met?
- Slide decks and videos
- What are the strategies for inhibiting the VEGF pathway?
- Gastric Cancer
- Traditional Monoclonal Antibodies
- Angiogenic Signaling
- HER Signaling
- Parsatuzumab (Anti-EGFL7)
- Anti-HER3/EGFR MAb (MEHD7945A)
- Anti-PDL1 (MPDL3280A)
- HER2:HER3 dimer
- Glossary
- HER1/EGFR evaluation
- HER1/EGFR in lung cancer
- HER1/EGFR in pancreatic cancer
- HER1/EGFR and prognosis
- Summary
- HER1/EGFR as a therapeutic target
- HER2 in breast cancer
- HER2 detection methods
- HER2 dysregulation
- HER2
- HER2 in ovarian cancer
- HER2 and prognosis
- Summary
- HER2 as a therapeutic target
- HER3 in breast cancer
- HER3 dysregulation
- HER3 evaluation
- HER3
- HER3 in ovarian cancer
- Summary
- HER3 as a therapeutic target
- HER4
- HER pathways slide decks and videos
- Receptor activation
- Cancer effects
- Dimerization
- Overview
- HER ligands
- HER receptors
- Summary
- Therapeutic potential of HER pathways
- Research MET
- What is Met?
- Glossary
- Slide decks and videos
- What are the strategies for inhibiting the VEGF pathway?
- Gastric Cancer
- Antibody-Drug conjugates
Dimerization Video
Potential Role of Dimerization
HER2+ Breast Cancer Slide Decks
Comprehensive overview of HER2 Dimerization Inhibitors (HDIs)
New: HER2 Dimerization iTunes app
Explore the potential of HER2 dimerization inhibition
View all downloadable resourcesThe structure of HER2: domains and dimerization
HER2 contains extracellular, transmembrane, and intracellular domains. While the intracellular domain is responsible for phosphorylation and recruitment of proteins, the extracellular domain is where signal transduction is initiated through dimerization with other receptors.13 Preclinical research continues to uncover the individual roles of each sub-domain in receptor activation and signaling.
- Select one to reveal more about HER2
- 1Sub-domain I
-
Extracellular sub-domain I and sub-domain III
Unlike other receptors in the HER family, sub-domain I on HER2 is constantly in contact with sub-domain III. Permanent interaction between these 2 sub-domains keeps the receptor in an open conformation, exposing sub-domain II, and ensuring the receptor is always ready to dimerize.3
- 2Sub-domain II
-
Extracellular sub-domain II
Sub-domain II is the dimerization domain. This domain enables HER2 to bind with other receptors in the HER family to initiate downstream signaling.3
- 3Sub-domain III
-
Extracellular sub-domain I and sub-domain III
Unlike other receptors in the HER family, sub-domain I on HER2 is constantly in contact with sub-domain III. Permanent interaction between these 2 sub-domains keeps the receptor in an open conformation, exposing sub-domain II, and ensuring the receptor is always ready to dimerize.3
- 4Sub-domain IV
-
Extracellular sub-domain IV
While the exact role of sub-domain IV in HER functioning is still unknown, it is believed to stabilize and lock the receptor in an open conformation. Other approaches to targeting HER2 bind to sub-domain IV to interfere with HER2 signaling, but sub-domain IV is not directly involved with dimerization. 13
- 5Transmembrane Domain
-
Transmembrane domain
The transmembrane domain of HER2 has been implicated in receptor activation control, but further research is required to understand its function in signaling initiation.13
- 6Intracellular Domain
-
Intracellular domain
The intracellular domain has a cytoplasmic linker, a tyrosine kinase component, and a tail that phosphorylates and recruits adapter proteins following dimerization.13 These adapter proteins can then initiate cell proliferation signaling, leading to cell growth, differentiation, and angiogenesis.12
- Go back to all Domains